Pneumococcal vaccination in the elderly. An underused option?

BioDrugs

Volumn 12, Issue 1, 1999, Pages 19-25

  Honkanen, Pekka Olavi ^a,c   Mäkelä, Pirjo Helena ^b  

^a UNIVERSITY OF OULU   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c NONE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G; PNEUMOCOCCUS VACCINE;

AGED; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EVIDENCE BASED MEDICINE; FEVER; GERIATRIC CARE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; LOBAR PNEUMONIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0032763501     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912010-00003     Document Type: Review

References (71)

1. 1. Pneumococcal and influenza vaccination levels among adults aged ≥65 years - United States, 1995. MMWR Morbid Mortal Weekly Rep 1997; 46 (39): 913-9
2. 2. Causes of Death. Helsinki: Statistics in Finland, 1996
3. 3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137 (9): 977-88
4. 4. Marston B, Plouffe J, File T, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157: 1709-18
5. 5. Fine M, Smith M, Carson C, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275 (2): 134-41
6. 6. Holmberg H. Aetiology of community-acquired pneumonia in hospital treated patients. Scand J Infect Dis 1987; 19: 491 -501
7. 7. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671-4
8. 8. The British Thoracic Society. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62: 195-220
9. 9. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multi-center study of 359 cases. Medicine 1990; 69: 307-16
10. 10. Moine P, Vercken J, Chevret S, et al. Severe community-acquired pneumonia. Etiology, epidemiology, and prognostic factors. Chest 1994; 105 (5): 1487-95
11. 11. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330-5
12. 12. Lieberman D, Lieberman D, Schlaeffer F, et al. Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. Age Ageing 1997; 26: 69-75
13. 13. Plouffe J, E, Breiman R, F., Facklam R, R. Bacteremia with Streptococcus pneumoniae Implications for therapy and prevention. JAMA 1996; 275: 194-8
14. 14. Sankilampi U, Herva E, Haikala R, et al. Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland. Epidemiol Infect 1997; 118: 7-15
15. 15. Pastor P, Medeley F, Murphy T. Invasive pneumococcal disease in Dallas County, Texas: Results from population-based surveillance in 1995. Clin Infect Dis 1998; 26: 590-5
16. 16. Austrian R. Pneumococcal pneumonia. Diagnostic, epidemiologic, therapeutic and prophylactic considerations. Chest 1986; 90 (5): 738-13
17. 17. Örtqvist Å, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990; 3 (10): 1105-13
18. 18. Kuikka A, Syrjänen J, Renkonen OV, et al. Pneumococcal bacteremia during a recent decade. J Infect 1992; 24: 157-68
19. 19. Honkanen P. [Pneumokokki-ja influenssarokotusohjelman toteuttaminen cläkeikäisessä väestössä] The pneumococcal and influenza vaccination program among the elderly [thesis]. Oulu: Oulu University Press, 1998
20. 20. Sisk J, Moskowitz A, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278 (16): 1333-9
21. 21. Baltussen RMPM, Ament AJHA, Leidel RM, et al. Cost-effectiveness opf vaccination against pneumococcal pneumonia in the Netherlands. Eur J Publ Hlth 1997; 7: 153-61
22. 22. Kragsbjerg P, Källman J, Olcén P. Pneumococcal meningitis in adults. Scand J Infect Dis 1994; 26: 659-66
23. 23. Schuchat A, Robinson K, Wenger J, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-6
24. 24. Finland M. Pneumonia and pneumococcal infections, with special reference to pneumococcal pneumonía. Am Rev Respir Dis 1979; 120: 481-502
25. 25. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60 (5): 759-76
26. 26. Marrie TJ. Bacteremic pneumococcal pneumonia: a continuously evolving disease. J Infect 1992; 24: 247-55
27. 27. Kramer MR, Rudensky B, Hadas-Halperin I, et al. Pneumococcal bacteremia-no change in mortality in 30 years: Analysis of 104 cases and review of the literature. Isr J Med Sci 1987; 23: 174-80
28. 28. Örtqvist A, Kalin M. Bacteremic pneumococcal pneumonía in Stockholm, Sweden, in 1984. Scand J Infect Dis 1988; 20: 451-2
29. 29. Lääveri T, Nikoskelainen J, Meurman O, et al. Bacteraemic pneumococcal disease in a teaching hospital in Finland. Scand J Infect Dis 1996; 28: 41-6
30. 30. Austrian R, Confronting drug-resistant pneumococci. Ann Intern Med 1994; 121 (10): 807-9
31. 31. Gold H, Moellering J. Antimicrobiological-drug resistance. N Engl J Med 1996; 335 (19): 1445-53
32. 32. Säynäjäkangas P, Keistinen T, Honkanen P, et al. Hospital discharges for pneumonia in Finland between 1972 and 1993 in the population aged 65 years or over. Age Ageing 1997; 26: 269-73
33. 33. Robbins J, Austrian R, Lee C-J, et al. Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148 (6): 1136-59
34. 34. Honkanen PO, Keistinen T, Kivelä S-L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156: 205-8
35. 35. Austrian R, Douglas R, M., Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89: 184-94
36. 36. Bruyn GA, van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis 1991; 10 (11): 897-910
37. 37. Willems JS, Sanders CR, Riddiough MA, et al. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303 (10): 553-9
38. 38. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104 (1): 79-86
39. 39. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-30
40. 40. Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-7
41. 41. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325 (21): 1453-60
42. 42. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270 (15): 1826-31
43. 43. Farr B, Johnston B, Cobb D, et al. Preventing pneumococcal bacteremia in patients at risk. Arch Intern Med 1995; 155: 2336-40
44. 44. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425-30
45. 45. Gaillat J, Zmirou D, Mallaret MR, et al. Essai clinique du vaccin antipneumococcique chez des personnes agées vivant en institution. Rev Epidemiol Sante Publique 1985; 33: 437-44
46. 46. Koivula I, Sten M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly. Am J Med 1997; 103: 281-90
47. 47. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of Veterans Administration cooperative study. N Engl J Med 1986; 315 (21): 1318-27
48. 48. Örtqvist A, Hedlund J, Burman L-A, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351: 399-403
49. 49. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17 (20-21): 2493-500
50. 50. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154 (23): 2666-77
51. 51. Melbye H, Dale K. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia. Acta Radiol 1992; 33 (1): 79-81
52. 52. Niederman M, Bass J, Campbell G, et al. Guidlines for the initial management of adults with community-acquired pneumonoa: diagnosis, assessment of severit, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
53. 53. Bartlett J, Mundy L. Community-acquired pneumonia: N Engl J Med 1995; 333 (24): 1618-24
54. 54. Leinonen M, Syrjälä H, Jalonen E, et al. Demonstration of pneumolysin antibodies in circulating immune complexes -a new diagnostic method for pneumococcal pneumonia. Serodiagn Immunother Infect Dis 1990; 4: 451-8
55. 55. Giesecke J. Modern infectious disease epidemiology. London: Arnold, 1994
56. 56. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1993; 8 (4): 285-93
57. 57. Macfarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect 1994; 9 (3): 153-65
58. 58. Moine P, Vercken J, Chevret S, et al. Severe community-acquired pneumococcal pneumonia. Scand J Infect Dis 1995; 27: 201-6
59. 59. Schlesselman JJ. Case-control studies. New York: Oxford University Press, 1982
60. 60. Simberkoff MS. Pneumococcal vaccine in prevention of community-acquired pneumonia; a skeptical view of cost-effectiveness. Semin Respir Infect 1993; 8 (4): 294-9
61. 61. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med 1994; 154 (4): 373-7
62. 62. Plouffe JF, File JTM. Pneumococcal vaccine: a different perspective. Arch Intern Med 1994; 154: 1995
63. 63. Ruben FL. Counterpoint to Pneumococcal vaccine after 15 years of use. Arch Intern Med 1995; 155: 771-2
64. 64. Fedson P, Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin Infect Dis 1998; 26: 1117-23
65. 65. Oxman AD, Sackett DL, Guyatt GH. Users' guide to the medical literature. I. How to get started. JAMA 1993; 270 (17): 2093-7
66. 66. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA 1993; 270 (21): 2598-601
67. 67. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271 (1): 59-63
68. 68. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of consequences of treatment. N Engl J Med 1988; 318: 1728-33
69. 69. Hook E, Horton C, Schaberg D. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249: 1055-7
70. 70. Gruer LD, McKendrick MW, Geddes AM. Pneumococcal bacteremia - a continuing challenge. Q J Med 1984; 210: 259-70
71. 71. Sackett DL, Richardson WS, Rosenberg W, et al. Evidence-based medicine. How to practice and teach EBM. Edinburgh: Churchill Livingstone, 1998